Summary
This prediction ended on 17.12.18 with a price of €6.36. The BUY prediction by melinda for Endologix performed very badly with a performance of -76.42%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Endologix | - | - | - | - |
| iShares Core DAX® | -3.033% | 0.651% | 12.268% | 18.187% |
| iShares Nasdaq 100 | -3.554% | -3.007% | 27.682% | 47.279% |
| iShares Nikkei 225® | -3.938% | 1.935% | 10.515% | 10.489% |
| iShares S&P 500 | -1.517% | -0.602% | 25.859% | 45.572% |
Comments by melinda for this prediction
In the thread Endologix diskutieren
SecteurEquipement, fournitures et distribution médicale Agenda 02/10 Investor Meeting
Develops and manufactures medical devices for the treatment of aortic disorders
Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA).
Its products include AFX Endovascular AAA System, Nellix and Ovation.
The company was founded in March 1992 and is headquartered in Irvine, CA.
Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA).
Its products include AFX Endovascular AAA System, Nellix and Ovation.
The company was founded in March 1992 and is headquartered in Irvine, CA.
Nombre d'employés : 675 personnes.
(Vom Mitglied beendet)